These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17117235)

  • 21. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
    Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
    Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    Budaj A; Eikelboom JW; Mehta SR; Afzal R; Chrolavicius S; Bassand JP; Fox KA; Wallentin L; Peters RJ; Granger CB; Joyner CD; Yusuf S;
    Eur Heart J; 2009 Mar; 30(6):655-61. PubMed ID: 18713759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety evaluation of enoxaparin in currently approved indications.
    Meneveau N
    Expert Opin Drug Saf; 2009 Nov; 8(6):745-54. PubMed ID: 19860536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of low-molecular-weight heparins during percutaneous coronary intervention.
    Martin JL; Slepian M
    J Invasive Cardiol; 2011 Jan; 23(1):1-8. PubMed ID: 21183762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Stroke. Enoxaparin sodium inhibits venous thromboembolism compared to unfractionated heparin].
    Drossbach M
    Med Monatsschr Pharm; 2007 Nov; 30(11):426. PubMed ID: 18062340
    [No Abstract]   [Full Text] [Related]  

  • 28. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
    Christy GW
    J Invasive Cardiol; 2008 Nov; 20(11):615-21. PubMed ID: 18987403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Low-molecular-weight heparins in acute coronary syndrome: acquired results and new perspectives].
    Ugo F; Ardissino D
    G Ital Cardiol (Rome); 2006 Dec; 7(12):771-9. PubMed ID: 17294602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
    Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic therapy in ST-segment elevation myocardial infarction.
    Wong CK; White HD
    Expert Opin Pharmacother; 2011 Feb; 12(2):213-23. PubMed ID: 21226633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does anticoagulation benefit patients with congestive heart failure (CHF) who have reduced left ventricular ejection fraction (LVEF) and are in normal sinus rhythm?
    Shah N; DeLeon D; Schwiebert LP; Mold JW
    J Okla State Med Assoc; 2009 Apr; 102(4):126-7. PubMed ID: 19504981
    [No Abstract]   [Full Text] [Related]  

  • 35. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Beta-blockers for protection against hypertensive target-organ damage].
    Takahashi F
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():583-6. PubMed ID: 15171440
    [No Abstract]   [Full Text] [Related]  

  • 37. [Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients].
    MMW Fortschr Med; 2006 Jun; 148(23):58-9. PubMed ID: 16826742
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
    Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
    Petersen JL; Mahaffey KW; Becker RC; Goodman SG; Kleiman NS; Marian AJ; Stone GW; Lansky AJ; Lincoff AM; Hazen SL; Nessel CC; Toro-Figueroa L; Tate L; Reist CJ; Cohen M; Califf RM; Ferguson JJ;
    Am Heart J; 2004 Aug; 148(2):269-76. PubMed ID: 15308996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
    Jonas S; Quartermain D
    Ann N Y Acad Sci; 2001 Jun; 939():268-70. PubMed ID: 11462779
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.